Key Highlights
● Immix released interim NEXICART-2 data on NXC-201 in relapsed or refractory AL amyloidosis on September 29, 2026.
● A summary said the interim data showed a high complete-response rate across all 45 patients treated in the study.
● All 25 newly enrolled patients had either achieved a complete response or were minimal residual disease negative, per that summary.
● Immix plans to release final data and file a Biologics license application with the FDA in mid-2027.
Immix Biopharma, Inc. (NASDAQ:IMMX) was one of the most talked-about small-cap biotech names on Tuesday, September 29, 2026, after releasing interim data from its NEXICART-2 Phase 2 trial of NXC-201 in relapsed or refractory AL amyloidosis. The stock was listed among the day's notable movers, though the size of its move was not reported.
What the Data Showed
NXC-201 is a CAR-T cell therapy, a treatment that reprograms a patient's own immune cells to attack diseased cells. It targets BCMA, a protein found on the surface of plasma cells, the source of the harmful proteins in AL amyloidosis. According to a summary of the company's release, the interim data showed a high complete-response rate across all 45 patients treated in the study. The summary added that all 25 newly enrolled patients had either achieved a complete response or were minimal residual disease, or MRD, negative.
Reading the Measures
A complete response, or CR, means signs of the disease are no longer detectable by standard tests. MRD negativity is an even more sensitive measure, meaning highly sensitive tests found no remaining trace of the abnormal cells. Both are key goals for therapies in blood-related disorders.
Why AL Amyloidosis Matters
AL amyloidosis is a rare and serious disease in which abnormal plasma cells in the bone marrow produce misfolded proteins called light chains. Those proteins clump into deposits, known as amyloid, that build up in organs such as the heart and kidneys and can cause organ failure. Patients whose disease relapses or does not respond to treatment have limited options, which is why strong response data in that setting draws attention.
The Path Ahead
Immix plans to release final data and file a biologics license application, the application needed to seek FDA approval, in mid-2027. Any further interim updates or regulatory interactions before then will be watched, as will comments on Manufacturing and funding plans ahead of a filing.
Biotech in a Tough Tape
The news contrasted with a rough day for parts of biotech. uniQure collapsed after four-year data for its Huntington's disease gene therapy missed statistical significance on a key measure, and health care stocks were among the decliners at midday. The Russell 2000 finished lower, with closing figures from different sources clustered between roughly 2,807 and 2,810. New York Fed President John Williams said there is no need for urgency after the central bank's September meeting, and odds of an October rate hike fell to roughly a coin flip. GDP and August PCE Inflation arrive on Wednesday, September 30, Nike reports on Thursday, October 1, and the September jobs report follows on Friday, October 2.






Please wait processing your request...